Department of Biochemical Engineering and Biotechnology, Indian Institute of Technology, Hauz Khas, New Delhi, 110016, India.
Department of Anesthesiology and Critical Care, Armed Forces Medical College, Pune, 411040, Maharashtra, India.
Diabetes Metab Syndr. 2021 Sep-Oct;15(5):102248. doi: 10.1016/j.dsx.2021.102248. Epub 2021 Aug 15.
This study aims to find a quantitative association between the presence of co-existing diabetes mellitus (DM) and/or hypertension (HTN) with COVID-19 infection severity and mortality.
A total of 813 patients with a positive COVID-19 were included. A case-control design was used to dissect the association between DM and HTN with COVID-19 severity and mortality.
According to MOHFW guidelines, 535 (65.7%) patients had mild, 160 (19.7%) patients had moderate, and 118 (14.5%) patients had severe disease outcomes including mortality in 52 patients. Age, Neutrophil%, and Diabetes status were significantly associated with severe COVID-19 infection. After adjusting for age, patients with diabetes were 2.46 times more likely to have severe disease (Chi-squared = 18.89, p-value<0.0001) and 2.11 times more likely to have a fatal outcome (Chi-squared = 6.04, p-value = 0.014). However, we did not find evidence for Hypertension modifying the COVID-19 outcomes in Diabetic patients.
COVID-19 severity and mortality both were significantly associated with the status of DM and its risk may not be modified by the presence of HTN.
本研究旨在探讨同时患有糖尿病(DM)和/或高血压(HTN)与 COVID-19 感染严重程度和死亡率之间是否存在定量关联。
共纳入 813 例 COVID-19 阳性患者。采用病例对照设计来剖析 DM 和 HTN 与 COVID-19 严重程度和死亡率之间的关联。
根据 MOHFW 指南,535 例(65.7%)患者为轻症,160 例(19.7%)患者为中度,118 例(14.5%)患者为重症,包括 52 例死亡。年龄、中性粒细胞%和糖尿病状况与严重 COVID-19 感染显著相关。在调整年龄后,患有糖尿病的患者发生重症疾病的可能性是未患糖尿病患者的 2.46 倍(卡方检验=18.89,p 值<0.0001),且发生致死性结局的可能性是未患糖尿病患者的 2.11 倍(卡方检验=6.04,p 值=0.014)。然而,我们并未发现 HTN 存在会改变糖尿病患者 COVID-19 结局的证据。
COVID-19 的严重程度和死亡率均与 DM 状况显著相关,其风险可能不受 HTN 的影响。